What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of investigation include Internal medicine, Renal cell carcinoma, Oncology, Melanoma and Immunology.
His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine.
Michael B. Atkins combines subjects such as Odds ratio, Kidney disease, Temsirolimus, Carcinoma and Antibody with his study of Renal cell carcinoma.
His study in Oncology is interdisciplinary in nature, drawing from both Avelumab, Colorectal cancer, Tolerability and Survival analysis.
His work in Melanoma tackles topics such as Ipilimumab which are related to areas like Dabrafenib, Vemurafenib and Trametinib.
His research in Immunology intersects with topics in Cancer and Cancer research.
His most cited work include:
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Final Version of 2009 AJCC Melanoma Staging and Classification (3479 citations)
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma (2311 citations)
What are the main themes of his work throughout his whole career to date?
Michael B. Atkins focuses on Internal medicine, Oncology, Renal cell carcinoma, Melanoma and Cancer.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
His Surgery research is multidisciplinary, incorporating elements of Alpha interferon and Toxicity.
His Oncology research also works with subjects such as
- Pembrolizumab that intertwine with fields like Cohort,
- Clinical trial that connect with fields like Randomized controlled trial.
His research integrates issues of Cancer research and Carcinoma in his study of Renal cell carcinoma.
Michael B. Atkins has included themes like Stage, Disease, Survival rate and Adjuvant therapy in his Melanoma study.
He most often published in these fields:
- Internal medicine (62.78%)
- Oncology (49.25%)
- Renal cell carcinoma (34.21%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (62.78%)
- Oncology (49.25%)
- Renal cell carcinoma (34.21%)
In recent papers he was focusing on the following fields of study:
Michael B. Atkins mostly deals with Internal medicine, Oncology, Renal cell carcinoma, In patient and Pembrolizumab.
His Internal medicine study often links to related topics such as Melanoma.
His work deals with themes such as Targeted therapy, Disease and Adjuvant therapy, which intersect with Melanoma.
His Oncology study combines topics in areas such as Checkmate, Advanced melanoma, Immunotherapy and Phases of clinical research.
His biological study spans a wide range of topics, including Sorafenib and Hazard ratio.
His research on Pembrolizumab concerns the broader Cancer.
Between 2018 and 2021, his most popular works were:
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (836 citations)
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (692 citations)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (302 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary scientific interests are in Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and Pembrolizumab.
His Clinical trial, Cohort, Survival rate, Targeted therapy and Adjuvant therapy study are his primary interests in Internal medicine.
Michael B. Atkins has researched Oncology in several fields, including Randomized controlled trial, Phases of clinical research and Carcinoma.
His Renal cell carcinoma research integrates issues from Sickle cell trait, Renal medullary carcinoma and Nephrectomy.
The study incorporates disciplines such as Ipilimumab and Melanoma in addition to Nivolumab.
Michael B. Atkins works mostly in the field of Pembrolizumab, limiting it down to topics relating to Axitinib and, in certain cases, Progression-free survival, First line therapy and Avelumab, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
